Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM5VH6U)

Drug Name
Serlopitant Drug Info
Synonyms
VPD-737; UNII-277V92K32B; CHEMBL447955; 860642-69-9; 277V92K32B; 3-((3aR,4R,5S,7aS)-5-((R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-4-(4-fluorophenyl)hexahydro-1H-isoindol-2(3H)-yl)cyclopent-2-enone; Serlopitant [USAN:INN]; VPD 737; Serlopitant (USAN); SCHEMBL3183159; GTPL9280; mk-0594; FLNYCRJBCNNHRH-OIYLJQICSA-N; BDBM50277511; compound 17 (Jiang et al. 2009); DB12973; D09378; 3-[(3aR,4R,5S,7aS)-5-{(1R)-1-[3,5-Bis(trifluoromethyl)phenyl]ethoxy}-4-(4-fluorophenyl)octahydro-1H-isoindol-2-yl]cyclopent-2-en-1-one
Indication
Disease Entry ICD 11 Status REF
Prurigo nodularis EC91.0 Phase 3 [1]
Psoriasis vulgaris EA90 Phase 2 [1]
Cross-matching ID
PubChem CID
23653789
CAS Number
CAS 860642-69-9
TTD Drug ID
DM5VH6U

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Substance-P receptor (TACR1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Aprepitant DM053KT Depression 6A70-6A7Z Approved [2]
Selegiline DM6034S Major depressive disorder 6A70.3 Approved [3]
Rolapitant DM8XP26 Chemotherapy-induced nausea MD90 Approved [4]
Netupitant DMEKAYI Chemotherapy-induced nausea MD90 Phase 3 [4]
LY-686017 DM7WORZ Atopic dermatitis EA80 Phase 3 [5]
Elinzanetant DMC6EFI Hot flushes GA30 Phase 3 [6]
CP-122721 DMSWLM5 Major depressive disorder 6A70.3 Phase 2 [7]
FR139317 DMEL5SV Hypertension BA00-BA04 Phase 2 [3]
VOFOPITANT HYDROCHLORIDE DMQMYP5 Vomiting MD90 Phase 2 [8]
LY-2590443 DM81UJW Migraine 8A80 Phase 2 [9]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Substance-P receptor (TACR1) TTZPO1L NK1R_HUMAN Antagonist [1]

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Potent, brain-penetrant, hydroisoindoline-based human neurokinin-1 receptor antagonists. J Med Chem. 2009 May 14;52(9):3039-46.
3 Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
4 Netupitant and palonosetron trigger NK1 receptor internalization in NG108-15 cells. Exp Brain Res. 2014 Aug;232(8):2637-44.
5 Stress-related neuropeptides and alcoholism: CRH, NPY and beyond. Alcohol. 2009 November; 43(7): 491-498.
6 Elinzanetant (NT-814), a Neurokinin 1,3 Receptor Antagonist, Reduces Estradiol and Progesterone in Healthy Women. J Clin Endocrinol Metab. 2021 Jul 13;106(8):e3221-e3234.
7 A review of drug options in age-related macular degeneration therapy and potential new agents. Expert Opin Pharmacother. 2006 Dec;7(17):2355-68.
8 Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenicchemotherapy: a randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009 Jun;10(6):549-58.
9 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 360).